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Abstract
Background: Routine cytogenetic investigations for ovarian cancers are limited by culture failure
and poor growth of cancer cells compared to normal cells. Fluorescence in situ Hybridization (FISH)
application or classical comparative genome hybridization techniques are also have their own
limitations in detecting genome imbalance especially for small changes that are not known ahead of
time and for which FISH probes could not be thus designed.
Methods: We applied microarray comparative genomic hybridization (A-CGH) using one mega
base BAC arrays to investigate chromosomal disorders in ovarian adenocarcinoma in patients with
familial history.
Results: Our data on 10 cases of ovarian cancer revealed losses of 6q (4 cases mainly mosaic loss),
9p (4 cases), 10q (3 cases), 21q (3 cases), 22q (4 cases) with association to a monosomy X and gains
of 8q and 9q (occurring together in 8 cases) and gain of 12p. There were other abnormalities such
as loss of 17p that were noted in two profiles of the studied cases. Total or mosaic segmental gain
of 2p, 3q, 4q, 7q and 13q were also observed. Seven of 10 patients were investigated by FISH to
control array CGH results. The FISH data showed a concordance between the 2 methods.
Conclusion: The data suggest that A-CGH detects unique and common abnormalities with certain
exceptions such as tetraploidy and balanced translocation, which may lead to understanding
progression of genetic changes as well as aid in early diagnosis and have an impact on therapy and
prognosis.
Background
A number of strategies have been used for early detection
of ovarian cancer and follow-up. CA-125 tumor marker
investigation and trans vaginal ultrasound are the most
common used procedures [1,2]. An increase of CA-125
marker has been shown to predate clinical or scan evi-
dence of relapse in approximately 70% of patient with
ovarian cancer [3]. For Genome disorders investigation
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classical cytogenetic, fluorescence in situ hybridization
and comparative genome hybridization methods were
applied in cancers [4-6]. Recent studies suggest that
genomic changes can be useful for cancer grading [7]. For
example, a study by Simon et al. [8] showed that break-
points in regions 1p3 and 11p1 are important early events
and distinguish a class of tumors associated with poor
prognosis in ovarian adenocarcinoma. Genomic changes
in ovarian cancers were investigated by using various tech-
niques, each with its own limitations. For example fluo-
rescence in situ hybridization was used by Liehr et al. [9],
on 25 cases of ovarian carcinomas using alphoid probes
noting loss of chromosomes 17 and 20 and gain of chro-
mosomes 7, 1, 8 and 11 [10]. Classical comparative
genomic hybridization was also used but is limited in
their resolution [11-14]. Gene expression and proteomics
arrays were applied to assess gene expression changes
which could be due to both genotype changes, regulation
pathway changes, or epigenetic [15-19]. Single nucleotide
polymorphism arrays were also used recently to detect
some micro deletions and amplifications in serous ovar-
ian carcinomas [20,21].
Array comparative genome hybridization (A-CGH) using
spotted bacterial artificial chromosomes (BACs), phage
artificial chromosomes (PACs), cDNAs or oligonucle-
otides provides distinct advantages in specificity, sensitiv-
ity and high resolution genome analysis [22-28].
Microarray CGH combined to immunohistochemical
analysis was applied for genes amplification and prognos-
tic markers analysis in ovarian cancer [29]
Micro arrays provide distinct advantages over conven-
tional and molecular cytogenetics (pre and post natal,
cancer and oncology) analysis because they have the
potential to detect the majority of microscopic and sub
microscopic chromosomes changes from any DNA
sources with or without whole genome amplification
[30,31]. Other advantage of A-CGH is the increase in res-
olution that can be achieved compared to chromosome-
based CGH. The only limitations of CGH (both conven-
tional and A-CGH) is the inability to detect polyploidy or
balanced chromosome abnormalities. But polyploidy can
be easily detected by FISH, micro satellite analysis or flow
cytométrie and balanced translocations will still be detect-
able using classic cytogenetics or FISH.
Results
The main endocrinological observation in these patients
was an excess of sex steroids production. Histological
findings revealed 9 of 10 patients with serous papillary
cystadenocarcinoma (eight grade III and one grade II), the
remaining patient showed endometrial carcinoma with
papillary aspects and squamous metaplasia (Table 1). The
data we obtained from A-CGH showed that all ten
patients have an abnormal genome profile with both
unique and common changes (Table 2 and Figures 1, 2,
3). The most common findings were loss of 6q (4 cases
with mosaic loss of 6q), 9p (4 cases), 10q (3 cases), 21q
(3 cases), 22q (4 cases) and gain of 8q and 9q (occurring
together in 8 cases) and gain of 12p. Two cases with
monosomy X were observed. A micro deletion of 17p ter-
minal was observed in 2 cases. Some cases showed also a
genomic profile with total or mosaic segmental gain on
chromosomes 2p, 3q, 4q, 7q and 13q. Seven of 10
patients (1, 2, 4, 5, 6, 7, and 9) were analyzed by FISH for
aneuploidy confirmation using a cocktail of bacs probes
for each specific abnormal chromosome region. We were
not able to analyze the remaining 3 patients because of
the limited material. The obtained data by FISH was in
concordance with the CGH array except the patient
number 1 and 9. For the 2 patients we couldn't confirm
the mosaic loss of 18 q for patient 1 and the segmental
loss of 12q22-12q23 for patient 9 (see Fig 4).
Discussion
While early detection predicts treatment success, fewer
than 25% of ovarian cancers are currently detected at stage
Table 1: Hystological Findings
N° case Name (initials) Age Grading Hystological Diagnosis
1 PG 44 pT3c pNO pMX; Stage III C grade G2 (AICC 2002) cystoadenocarcinoma
2 TS 37 PTla pNO pMx Stage lA (AlCC2002) Endometrial carcinoma of the right ovary with papillary aspects and 
squamous metaplasia
3 VM 65 PTI b pNO G3 Stage IB (AlCC 2002) Cystoadenocarcinoma serous Papillary left and right ovary G 3
4 LR 84 PT2a pNX pMX Stage 2A G3 (AlCC 2002) Stage IIA 
FIGO)
Cystoadenocarcinoma, serous papillary left and right ovary G3
5 AW 75 Stage IV G3 Cystoadenocarcinoma, serous papillary G3
6 FR 73 pT2a pNI pMX Stage IIIC (AlCC 2002) Cystoadenocarcinoma serous papillary left ovary G3
7 PL 50 PT2a pNX pMX Stage 2A G3 (AlCC 2002) Stage IIA 
FIGO)
Cystoadenocarcinoma serous papillary left and right ovary G3
8 MA 64 PT2a pNX pMX Stage 2A G3 (AlCC 2002) Stage IIA 
FIGO
Cystoadenocarcinoma serous papillary left and right ovary G3
9 MF 68 PT3c pN1 pMX Stage mc G3 (AlCC 2002) Cystoadenocarcinoma serous papillary left ovary
10 WDT 45 PT3c pN1 pMX Stage IIIC G3 (AlCC 2002) Cystoadenocarcinoma serous papillary left and right ovary G3Molecular Cytogenetics 2008, 1:10 http://www.molecularcytogenetics.org/content/1/1/10
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Table 2: Genome profile results of the 10 patients
N° Name Segmental gain Segmental loss Other abnormalities
l PG Segmental gain on 2p, 7q, and 13 q arms Mosaic segmental loss on 10 q and 18 q 
arms
2 TS Segmental gain on 8q, 9q, 12p, and 13q arms Total loss of 9p and 10q arms Monosomy 21 and 22
3 VM Mosaic segmental gain on 3q and 4q arms Total gain of 7q, 8q, 
9q, 13q arms
Mosaic segmental loss on 6q arms Monosomy 22
4 LR Mosaic segmental gain on 3q and 4q Total gain of 2p, 7q, 8q, 
9q 13q and 17q arms
Mosaic segmental loss on 6q arms Monosomy 21
5 AW Segmental gain on 12p arms Total loss of chromosome 10 Segmental disorder of chromosome 13 
monosomy 21 and X
6 FR Segmental gain on 8q, 9q, 12p and 13q arms Segmental loss on 9p arm Monosomy 22 and X
7 PL Segmental gain on 2p, 7q, 8q, 9q, 12p,13q arms Mosaic segmental loss on 6q, 7p and 
10p arms
8 MA Segmental gain on 2p, 8q and 9q arms Mosaic segmental gain 
on 12p arm
Segmental loss on 9p arm Cryptic loss of tel 17p
9 MF Segmental gain on 8q and 9q arms Mosaic segmental gain 12p 
arm
Segmental loss on 9p arm Cryptic loss of tel 17p
10 WDT Segmental gain on 8q, 9q and 13q arms Segmental mosaic loss on 6q arm Monosomy 22
examples of chromosomes profiles and abnormalities Figure 1
examples of chromosomes profiles and abnormalities.
Gain on 2p24-2pTer and 2p21-2p22 Gain on 8q11-8q22 and 8q24-8qTer Loss on 9p13-9p24;  gain on 9q31-9q34.1 Gain on 12p13-12pTer; Loss on 12q22-12q33
Loss on 13q11-13q13;
Loss of chromosome 21: Monosomy Loss of chromosome 22:Monosomy Loss of chromosome X: Monosomy gain on 13q13-q14 and 13q22-13qTerMolecular Cytogenetics 2008, 1:10 http://www.molecularcytogenetics.org/content/1/1/10
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I [32]. Approaches to ovarian screening include transvagi-
nal sonography, serum CA-125 markers or both, but these
include limitations in sensitivity and specificity [33]. A
rapid fall of CA 125 during chemotherapy predicts a favo-
rable prognosis and could be used to redistribute patients
on randomized clinical trials [34]. Gene expression and
proteomic arrays were used to identify markers that can be
used in combination with the clinical picture for early
detection [35].
We observed both qualitative and quantitative differences
as well as similarities between our data from array CGH
on these ovarian tumors from familial cases and abnor-
malities noted by classical G-banding techniques or other
molecular cytogenetic methods in the literature [36]. We
noted for example 8 of the ten cases with gain of 8q and
9q.
G-band studies remain the gold standard in cytogenetics
laboratories, but most such studies were carried on more
advanced cancers and reveal significant abnormalities
related to acquision of nuclear instability [37-
39,29,40,41]. Tharapel et al [42] reported a correlation
between chromosome abnormalities and cancer stages
such as presence of trisomy 7 and 10 in early stages of
ovarian adenocarcinoma. In one of the largest studies,
Tibiletti et al. [43] performed cytogenetic characterization
of a cohort of 114 untreated ovarian epithelial tumors and
concluded that there are three groups: "the first group
included abnormalities common to all tumor classes
(losses of chromosomes 6, 8, 10, 11, 15, 16, 17, 18, 19,
20, 21, 22, and X; gains of chromosomes 1, 3, 5, and 12
and 6q24-6qter deletions); the second group with specific
abnormalities present in malignant but not in benign
tumors (losses of chromosomes 2, 7, 13, and 14; gains of
chromosome 4 and chromosome markers); and the last
group included abnormalities unique to invasive carcino-
Genome profiling of patients 1 to 5 Figure 2
Genome profiling of patients 1 to 5.Molecular Cytogenetics 2008, 1:10 http://www.molecularcytogenetics.org/content/1/1/10
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mas (loss of chromosome 4; gains of chromosomes 2, 7,
8, 9, 10, 16, 17, 18, 19, 20, and 21; 6q16-6q24 deletions;
rearrangements of 3p, 3q, 13q, and 21q regions). The
analysis of 17 sporadic primary ovarian carcinomas by a
combination of spectral karyotyping, CGH and expres-
sion microarrays and when the distribution of aberrations
was normalized with respect to relative genomic length,
chromosomes 3, 8, 11, 17 and 21 had the highest frequen-
cies [44]. From in vitro murine model for ovarian cancer
the application of microarrays CGH revealed genomic
imbalances of chromosomes 4, 5, 7, 8, 9, 11, 15, 17 and X
[45].
Aneuploidy assessment in interphase cytogenetics of
chromosome 1, 11, 17 and X by fluorescence in situ
hybridization (FISH) of 92 epithelial ovarian tumors
identified numerical aberrations in 67% of mucinous car-
cinoma and 82% of invasive serous carcinomas but with-
out significant relationship with either stromal invasion
or tumor type except for monosomy X which was noted in
invasive serous carcinoma [46]. An investigation of 7 stage
III ovarian serous cancers by comparative genomic
hybridization (CGH) revealed chromosomal aberrations
in six patients with certain repeated changes including
increased copy numbers of 1q, 2p, 2q, 3q, 6q, 8q, and
12p, and loss of 18q and X [47]. CGH analysis of malig-
nant peripheral primitive neuroectodermal ovarian
tumors revealed different chromosomal abnormalities
including loss of chromosomes 1p, 1q, 4q, 6p, 6q, 7q, 8q,
13q and 19q; as well as gain of 1q, 2p, 7p, 9q, 18q and Xq
[48-50]. The use of CGH and tissue microarrays in ovarian
carcinoma [51] showed a frequent chromosomal over
presentation on 2q, 3q, 5p, 8q, 11q, 12p, 17q and chro-
mosome 20 combined to an amplification of 59 different
oncogenes loci.
Our data showed a loss of chromosome 10 or 10q mate-
rial in three cases and 6q material in 4 cases. Loss of het-
Genome profiling of patients 6 to 10 Figure 3
Genome profiling of patients 6 to 10.Molecular Cytogenetics 2008, 1:10 http://www.molecularcytogenetics.org/content/1/1/10
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erozygosity (LOH) on 10q23 involving PTEN tumor
suppressor gene is noted in about 30% of adenocarci-
noma and was suggested as an important event in the pro-
gression of endometriosis to ovarian adenocarcinoma
[52]. By FISH analysis Trisomies 1, 7 and monosomies 9
and 17 were observed in endometriosis, ovarian endome-
trioid adenocarcinoma and normal endometrium but the
frequency of aneusomic cells was significantly higher in
ovarian endometrioid carcinoma [10]. This may reflect an
expansion of aberrant cells clones already present in
endometriosis during the progression to cancer. Levan et
al. [13] examined 98 endometrioid adenocarcinomas by
CGH and reported 39 chromosomal regions displaying
frequent DNA copy number alterations. The analysis of 81
ovarian cancers for LOH by Obata and Hoshiai [53]
showed 60% with LOH on chromosome 6q and 40% on
Examples of FISH data using BACs probes Figure 4
Examples of FISH data using BACs probes. A) Case 2: trisomy 8q and 13q B) Case 5: trisomy 12p and monosomy X. C) 
Case 6: disomy 9q monosomy 9p D) Case 10: monosomy 6q monosomy 22.Molecular Cytogenetics 2008, 1:10 http://www.molecularcytogenetics.org/content/1/1/10
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10q. Their data supported the hypothesis that endometri-
oid and ovarian carcinoma may arise though malignant
transformation of endometriotic lesions.
Previous cytogenetics studies of adult germ cells tumors
(GCTs) showed that 12p abnormalities are common phe-
nomenon in more than 80% of GCTs. Our data showed 6
out 10 patients with segmental gain of 12 and mainly tri-
somy 12p. The presence of three or mores copies of 12p
may predict resistance to chemotherapy and treatment
failure [54].
In our data we observed 3 cases with monosomy 21 and 4
cases with monotony 22. The profiling of human chromo-
some 22 in ovarian carcinoma by Bentkiewicz et al [55]
using high resolution gene copy and expression analysis
detected 11 of 18 cases (60%) with heterozygous dele-
tions with various sizes in chromosome 22q and one case
with total monosomy 22q. One of the major observations
in this study is the presence of segmental gain of 8q and
9q in eight of 10 cases. Several of these cases also had 9p
loss. To predict a potential markers of chemo resistant dis-
ease, the analysis of chromosomal changes in serous ovar-
ian carcinoma by high resolution array CGH [14] revealed
a frequent increase in DNA copy number on 1p36, 3q26,
8q24, 10q26, 12p11, 20q13 and 21q22 and frequent loss
on 4p12, 5q13, 7q11, 8p23, 14q32, Xq13 and Xq21.
From these data Kim et al [14] conclude that the most reli-
able combination of chromosomal aberrations for detect-
ing chemo resistant disease was the loss on 13q32.1,
8p21.1. and 16p13 [56].
For genome profiling and high resolution molecular kary-
otyping, array comparative genome hybridisation (array
CGH) methods appear to be far better as they do not suf-
fer from dependence on having metaphase preparations
and have much higher sensitivity and specificity for subtle
genomic changes. Constitutional deletions as small as 40
kb have been detected using an array encompassing a 7
Mb interval of chromosome 22 with 90% coverage [57].
A-CGH can also provide a technically less demanding and
more sensitive assay than classic CGH or even routine
cytogenetics. A-CGH use is limited by the cost effective of
this technology in routine cytogenetics laboratory and
also by the ability to detect certain abnormalities such as
tetraploidy and balanced translocations
Conclusion
It appears likely that in the next few years, array based
CGH will become routinely used in clinical cytogenetics.
The profiling studies of ovarian cancer by molecular kary-
otyping and Multiplex ligation-dependent probe amplifi-
cation [58], expression micro arrays and MicroRNA
signature [16,19] and proteome analysis will open the
way to more exhaustive and systematic representation of
the disease and will provide valuable information that
may be helpful to elucidate the mechanism and the evo-
lution of ovarian cancer [17].
Materials and methods
Tumor tissues were available from ten women with a
familial history of ovarian carcinoma who underwent sur-
gery for ovarian masses which required hysterectomy with
bilateral ovariectomy at the University of Rome La
Sapienza, Saint Andrea Hospital. The mean age of the ten
patients studied was 60.5 yrs old.
We used human genomic micro arrays containing 2700
human/BAC/PAC clones (Human BAC Array-System, Per-
kin Elmer. USA). This array includes subtelomeric regions
as well as critical areas spaced roughly 1 Mb along each of
the human autosomes as well as the X and Y chromo-
somes. For consistency and increased sensitivity and spe-
cificity, the arrayed clones were printed in duplicate. 2 μg
each of the test DNA extracted from the tumor samples
and control DNA (female from Promega, Madison, WI)
were digested with 80 units of EcoR1 at 37°C overnight
and then purified by Zemo Research's column (Orange,
CA, USA). The test and reference DNAs were labeled with
Cy3 and Cy5 using random prime labeling kit (Invitro-
gen, Carlsbad, California) to obtain a labeled probe size
averaging 100 to 500 bp in length. Cy5 labeled test DNA
and Cy3 labeled reference DNA were co-precipated with
65 μg of Cot-1 DNA and 35 μg of Salmon sperm DNA.
Forward and reverse hybridization switching of dyes was
performed to address issues related to dye specificity and
strength. Then the probes were dissolved in 10 μl of dis-
tilled water and mixed with 50 μl of hybridization solu-
tion (50% formamide, 10% dextran sulphate in 2× SSC).
The hybridization mix then was denatured at 73°C for 12
min and followed by 40 min al 37° for annealing. For
hybridization and washing we used an automated system
(Tray Mix) based on chaotic hybridization approach and
developed by BIOTRAY sarl (69007 Lyon France).
Hybridized and washed array slides were analyzed with
InnoScan 700A scanner (INNOPSYS, 313901 Carbonne,
France). The software recognizes the regions of fluorescent
signal, determines signal intensity and compiles the data
into a spreadsheet that links the fluorescent signal of every
clone on the array to the clone name, its duplicate posi-
tion on the array and its position in the genome. The soft-
ware was also used to normalize the Cy5:Cy3 intensity
ratios for each data point. Normalization was such that
the summed Cy5 signal equals the summed Cy3 signal.
The normalized Cy3:Cy5 intensity ratios were computed
for each two slides and plotted together for each chromo-
some. The linear order of the clones in reconstituted in the
ratio plots consistent with an ideogram, such that the pMolecular Cytogenetics 2008, 1:10 http://www.molecularcytogenetics.org/content/1/1/10
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terminus in to the left and the q terminus in to the right of
the plot.
For data analysis we assign a ratio plot such that gains in
DNA copy number at particular locus are observed as the
simultaneous deviation of the ratio plots from a modal
value of 1.0, with the blue ratio plot showing a positive
deviation (upward) while the red ratio plot shows a nega-
tive deviation at the same locus (downward). DNA copy
number losses show the opposite pattern. In selected
cases, fluorescent in situ hybridization (FISH) was used to
confirm the A-GCH findings.
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